Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Drug Toxicity: Overview01:00

Drug Toxicity: Overview

Drug toxicity quantifies the harm a compound causes to an organism, varying by dose and potentially impacting whole systems or specific organs like the liver. Toxic reactions may arise from venomous insect or spider bites, with effects ranging from mild symptoms to severe outcomes such as brain damage or death. Common forms of acute poisoning include ethanol intoxication and overdose of pain or fever medications, with substances like GHB and heroin being particularly lethal at doses close to...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Deep Learning for the Prediction of Treatment Responses in Individuals With Epilepsy: Can We Get to Seizure Freedom Faster?

Neurology·2025
Same author

Driving in people with seizures and epilepsy.

The Lancet. Neurology·2025
Same author

Improving the tolerability of antiseizure medications: When and how to use cenobamate and other new antiseizure medications.

Epilepsia·2025
Same author

Seizures, Driver Licensure, and Medical Reporting Update: An AAN Position Statement.

Neurology·2025
Same author

Presurgical Use of Cenobamate for Adult and Pediatric Patients Referred for Epilepsy Surgery: Expert Panel Recommendations.

Neurology and therapy·2024
Same author

Prospective multicenter study of continuous tonic-clonic seizure monitoring on Apple Watch in epilepsy monitoring units and ambulatory environments.

Epilepsy & behavior : E&B·2024
Same journal

Clinical Failure Validates a Fifth Predictive Preclinical Antiseizure Medicine Discovery Model.

Epilepsy currents·2026
Same journal

Hearing in Our Sleep-Can We Drown Out Epileptic Spikes and Boost Cognition?

Epilepsy currents·2026
Same journal

Sleep Smarter: Optimal Sleep May Preserve Cognition and Reduce Dementia Risk in Focal Epilepsy.

Epilepsy currents·2026
Same journal

Microglia-Mediated Disinhibition: Taking the Brakes off Epileptic Networks.

Epilepsy currents·2026
Same journal

Brainstem Disinhibition Destabilizes Breathing in Dravet Syndrome, Leading to Sudden Unexpected Death in Epilepsy (SUDEP).

Epilepsy currents·2026
Same journal

Agree to Disagree: Reliability of Seizure Frequency Assessments.

Epilepsy currents·2026
See all related articles

Related Experiment Video

Updated: Jun 19, 2026

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

Evaluating risks for vigabatrin treatment.

Gregory L Krauss1

  • 1Johns Hopkins Department of Neurology Baltimore, Maryland, USA. gkrauss@jhmi.edu

Epilepsy Currents
|October 15, 2009
PubMed
Summary
This summary is machine-generated.

Vigabatrin treatment for epilepsy can cause irreversible vision loss in adults and brain abnormalities in infants. Careful risk-benefit assessment is crucial, especially for severe epilepsy cases.

Related Experiment Videos

Last Updated: Jun 19, 2026

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

Area of Science:

  • Neurology
  • Ophthalmology
  • Pharmacology

Background:

  • Vigabatrin is used to treat epilepsy, including infantile spasms.
  • Chronic use in adults is associated with visual field constriction.
  • Infants treated with vigabatrin may show brain MRI abnormalities.

Purpose of the Study:

  • To review the benefits of vigabatrin.
  • To outline the risks of vigabatrin to vision and brain development.
  • To identify patient subgroups who may still benefit from vigabatrin.

Main Methods:

  • Literature review of vigabatrin's effects.
  • Analysis of reported visual field deficits in adults.
  • Review of neuroimaging findings in infants.

Main Results:

  • 30-40% of adults develop visual field constriction, often irreversible.
  • Visual deficits are typically mild and asymptomatic.
  • Infants may develop intramyelinic edema in subcortical structures.

Conclusions:

  • Vigabatrin offers benefits for severe epilepsy but carries significant risks.
  • Careful consideration of risks versus benefits is essential for treatment decisions.
  • Treatment may be warranted in specific severe epilepsy cases despite risks.